ReviewCurrent neurology and neuroscience reports2018
Management of Brain Metastases in the New Era of Checkpoint Inhibition.
Review in Current neurology and neuroscience reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis.JAMA network open · 2022Pooled it
- Integrative Bioinformatic Analysis Identifies Key Genes Driving Breast Cancer Brain Metastasis.Diagnostics (Basel, Switzerland) · 2026Article
- Evolutionary Trend Analysis of Research on Immunotherapy for Brain Metastasis Based on Machine-Learning Scientometrics.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Article
- Efficacy of First-Line Immunotherapy Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients With Different Brain Metastases Status: A Systematic Review and Meta-Analysis.World journal of oncology · 2023Article
- An Overview of Systemic Targeted Therapy in Renal Cell Carcinoma, with a Focus on Metastatic Renal Cell Carcinoma and Brain Metastases.Current issues in molecular biology · 2023Review
- Changes in the characteristics of patients treated for brain metastases with repeat stereotactic radiotherapy (SRT): a retrospective study of 184 patients.Radiation oncology (London, England) · 2023Article
- Review
- Conjugation of a Blood Brain Barrier Peptide Shuttle to an Fc Domain for Brain Delivery of Therapeutic Biomolecules.ACS medicinal chemistry letters · 2021Article
- Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.The oncologist · 2021Article
- Clinical case of lung spindle cell carcinoma markedly responsive to pembrolizumab.Thoracic cancer · 2021Article
- Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.Cancer medicine · 2021Article
- Genomic Analysis Uncovers Immune Microenvironment Characteristics and Drug Sensitivity of Ferroptosis in Breast Cancer Brain Metastasis.Frontiers in genetics · 2021Article
- The promising role of radiotherapy in the treatment of advanced or metastatic renal cell carcinoma: a narrative review.Translational andrology and urology · 2020Review
- Association of Immunotherapy With Survival Among Patients With Brain Metastases Whose Cancer Was Managed With Definitive Surgery of the Primary Tumor.JAMA network open · 2020Article
- Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2020Article
- Article
- The Evolving Role of CD8International journal of molecular sciences · 2019Review
- Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRI.Journal of neuro-oncology · 2019Article
- Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology.Theranostics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewBrain metastasis is a common complication of advanced malignancies, especially, lung cancer, breast cancer, renal cell carcinoma, and melanoma. Traditionally surgery, when indicated, and radiation therapy, either as whole-brain radiation therapy or stereotactic radiosurgery, constituted the major treatment options for brain metastases. Until recently, most of the systemic chemotherapy agents had limited activity for brain metastases. However, with the advent of small molecule tyrosine kinase inhibitors and immunotherapy agents, there has been renewed interest in using these agents in the management of brain metastases. RECENT
findingsImmune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, lung cancer, kidney cancer, and bladder cancer among others. They modulate the immune system to recognize tumor antigens as "non-self" antigens and mount an immune response against them. Initial studies of using immune checkpoint inhibitors in brain metastases have shown promising activity, and several clinical trials are currently underway. Studies are also assessing the combination of radiation therapy and immunotherapy in brain metastases. The results of these ongoing clinical trials have the potential to change the therapeutic paradigm in patients with brain metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.